Inside the legal fight slowing down cheaper GLP-1 drugs

The push to make weight loss drugs more affordable is running into legal limits. Telehealth company Hims & Hers pulled a less expensive oral version of Wegovy after lawsuits from Novo Nordisk and rising regulatory scrutiny. The dispute centers on pharmaceutical compounding, which is legal for individualized patient needs, and whether it crossed into large-scale marketing. With semaglutide no longer in shortage, Novo says compounded versions are not justified. CNBC's Brandon Gomez reports.